Q-omics provides the consensus-scored PLXNA4 profile across patient tissues and cancer cell-line models. PLXNA4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLXNA4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PLXNA4 RNA expression shows 16,670 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where PLXNA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXNA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXNA4 survival associations across molecular data types. PLXNA4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXNA4 RNA expression–survival associations across cancer types. High PLXNA4 expression shows unfavorable associations in UVM, BLCA, DLBC and UCEC, but favorable associations in UCS and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLXNA4 RNA expression.
This table summarizes PLXNA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PLXNA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXNA4 shows lower tumor expression in KIRC, KICH, KIRP, BRCA and LIHC and higher tumor expression in THCA. The KIRC box plot shows higher PLXNA4 RNA expression in normal versus tumor tissue (log2 FC = −1.381, t-test p < 0.001).
This table shows molecular features associated with PLXNA4 in patient tissues and cancer cell lines. In patient samples, PLXNA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXNA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
